AR034091A1 - Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno - Google Patents

Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno

Info

Publication number
AR034091A1
AR034091A1 ARP000103450A ARP000103450A AR034091A1 AR 034091 A1 AR034091 A1 AR 034091A1 AR P000103450 A ARP000103450 A AR P000103450A AR P000103450 A ARP000103450 A AR P000103450A AR 034091 A1 AR034091 A1 AR 034091A1
Authority
AR
Argentina
Prior art keywords
straight
branched chain
group
strogen
receiver
Prior art date
Application number
ARP000103450A
Other languages
English (en)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of AR034091A1 publication Critical patent/AR034091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición farmacéutica que comprende un diluyente o vehículo aceptable para uso farmacéutico, una cantidad aceptable en términos terapéuticos de un modulador selectivo del receptor de estrógeno que tiene la fórmula general (1) donde R1 y R2 se seleccionan independientemente del grupo que consiste en hidrógeno, oxhidrilo, -OM (M se elige de entre el grupo que consiste en alquilo C1-4 de cadena lineal o ramificada, alquenilo C3-4 de cadena lineal o ramificada, alquinilo C3-4 de cadena lineal o ramificada) y una unidad convertible a oxhidrilo in vivo; G es -H ó -CH3; R3 es una especie que se selecciona del grupo consistente en pirrolidinilo, piperidino, morfolino, y NRaRb (Ra y Rb son independientemente hidrógeno, alquilo C1-6 de cadena lineal o ramificada, alquenilo C3-6 de cadena lineal o ramificada, y alquinilo C3-6 de cadena lineal o ramificada), y un precursor de esteroide sexual que se elige de entre el grupo que consiste en dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-3-eno-3b, 17b-diol y compuestos que se convierten a los anteriores in vivo. Métodos para el tratamiento médico y/o la prevención de la obesidad, la grasa abdominal y la resistencia a la insulina en animales de sangre caliente susceptibles, incluido el ser humano, que consisten en la administración de los moduladores selectivos de los receptores de estrógeno (SERM). También se describe una combinación de un SERM con una cantidad de estrógeno o un procursor de esteroides sexuales seleccionados del grupo formado por dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-3-eno-3b, 17b-diol y compuestos convertidos in vivo en uno de los precursores mencionados o estrógeno. Compuesto que tiene la estructura molecular de fórmula (2).
ARP000103450A 1999-07-06 2000-07-06 Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno AR034091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06

Publications (1)

Publication Number Publication Date
AR034091A1 true AR034091A1 (es) 2004-02-04

Family

ID=22499734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103450A AR034091A1 (es) 1999-07-06 2000-07-06 Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno

Country Status (25)

Country Link
US (2) US6710059B1 (es)
EP (1) EP1196163B1 (es)
JP (1) JP4790178B2 (es)
KR (1) KR101141763B1 (es)
CN (1) CN1390126B (es)
AR (1) AR034091A1 (es)
AT (1) ATE447947T1 (es)
AU (3) AU5957500A (es)
BR (1) BR0012354A (es)
CA (1) CA2376158C (es)
DE (1) DE60043305D1 (es)
DK (1) DK1196163T3 (es)
HK (1) HK1046240B (es)
HU (1) HU230543B1 (es)
IL (2) IL147485A0 (es)
MX (1) MX270786B (es)
MY (1) MY134574A (es)
NO (1) NO329614B1 (es)
NZ (1) NZ516453A (es)
PL (1) PL208972B1 (es)
RU (3) RU2327461C2 (es)
TR (2) TR200403328T2 (es)
TW (1) TWI359015B (es)
WO (1) WO2001001969A2 (es)
ZA (1) ZA200200085B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060098399A (ko) * 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
DE60043305D1 (de) * 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
RU2342145C2 (ru) * 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
WO2003027114A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
WO2004054573A1 (en) * 2002-12-13 2004-07-01 N.V. Nutricia Method and composition for inhibiting carbohydrate digestion
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
KR20080031037A (ko) * 2005-06-29 2008-04-07 와이어쓰 결합형 에스트로겐과 바제독시펜의 제형
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CA2667228C (en) * 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
CN101854962B (zh) * 2007-04-17 2015-12-16 米歇尔技术公司 具有生物降解性层的支架
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
JP5608160B2 (ja) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド 生体吸収性の層を有するステント
EP2313122B1 (en) * 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
WO2010111196A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Peripheral stents having layers
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
JPWO2011007882A1 (ja) * 2009-07-16 2012-12-27 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
HK1244808A1 (zh) * 2015-12-22 2018-08-17 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
US20180207264A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Porcine immune modulation model
EP4157448A4 (en) 2020-06-02 2024-09-04 Model Medicines, Inc. METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
ZA931601B (en) * 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
AU8433898A (en) * 1997-07-10 1999-02-08 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
HUP0002852A3 (en) * 1997-08-15 2001-11-28 Univ Durham A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives
EP1021191B1 (de) * 1997-10-08 2002-06-05 Genesiscosmetics Rights & Licenses Company Limited Straffung und/oder verkleinerung von fettzellen-haltigen körperpartien
HRP20000778B1 (en) 1998-05-15 2004-10-31 Wyeth Corp 2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens
KR20060098399A (ko) 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
DE60043305D1 (de) * 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz

Also Published As

Publication number Publication date
WO2001001969A2 (en) 2001-01-11
EP1196163A2 (en) 2002-04-17
AU5957500A (en) 2001-01-22
HUP0202363A3 (en) 2005-02-28
MXPA02000075A (es) 2003-05-23
DE60043305D1 (de) 2009-12-24
IL147485A0 (en) 2002-08-14
CA2376158A1 (en) 2001-01-11
MX270786B (es) 2009-10-08
NO329614B1 (no) 2010-11-22
JP2003503446A (ja) 2003-01-28
US6710059B1 (en) 2004-03-23
AU2005229713A1 (en) 2005-12-01
TR200403328T2 (tr) 2005-03-21
MY134574A (en) 2007-12-31
HK1046240B (en) 2010-09-30
TW200803838A (en) 2008-01-16
IL195860A (en) 2013-06-27
HUP0202363A2 (en) 2002-10-28
DK1196163T3 (da) 2010-03-29
TWI359015B (en) 2012-03-01
CA2376158C (en) 2011-03-15
RU2636498C2 (ru) 2017-11-23
NO20020037D0 (no) 2002-01-04
NO20020037L (no) 2002-03-04
EP1196163B1 (en) 2009-11-11
RU2327461C2 (ru) 2008-06-27
RU2013148518A (ru) 2015-05-10
RU2008101793A (ru) 2009-07-27
ZA200200085B (en) 2003-06-25
ATE447947T1 (de) 2009-11-15
US20040034000A1 (en) 2004-02-19
TR200502284T2 (tr) 2005-08-22
KR20020020776A (ko) 2002-03-15
KR101141763B1 (ko) 2012-05-08
BR0012354A (pt) 2002-04-02
JP4790178B2 (ja) 2011-10-12
US8609695B2 (en) 2013-12-17
CN1390126B (zh) 2012-06-13
PL208972B1 (pl) 2011-07-29
WO2001001969A3 (en) 2001-08-02
CN1390126A (zh) 2003-01-08
HU230543B1 (hu) 2016-11-28
AU2009200258B2 (en) 2012-01-12
RU2519642C2 (ru) 2014-06-20
HK1046240A1 (en) 2003-01-03
AU2009200258A1 (en) 2009-02-26
NZ516453A (en) 2004-04-30
PL352993A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
AR043075A1 (es) Un metodo para tratar o reducir el riesgo de adquirir una afeccion; una composicion farmaceutica y un kit utiles en dicho metodo
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
CA2467222A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
BRPI0516243B8 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
SE9902987D0 (sv) Novel compounds
BR0114801A (pt) Composto modulador receptor de androgênio seletivo de tecido, composição, composição farmacêutica, método para a ligação de um composto modulador receptor de androgênio seletivo a um receptor de androgênio, método para a modulação da espermatogênese em um indivìduo, método de terapia hormonal, método para o tratamento para um indivìduo tendo uma condição relacionada a um hormÈnio, método para o tratamento para um indivìduo tendo c‰ncer prostático e método para a determinação da presença de um composto
RU2010121160A (ru) Спиросоединения и их фармацевтическое применение
PE20041065A1 (es) Composiciones farmaceuticas que comprenden ester de testosterona y aceite de ricino
UY27436A1 (es) Compuestos químicos
MX2010003698A (es) Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
JP2022183311A (ja) 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
AR046756A1 (es) Derivados de hidronopol como agonistas de receptores orl-1 humanos.
CN1681513A (zh) 用于癌症治疗的含有雌四醇衍生物的药物组合物
AR057217A1 (es) Polimorfos de un modulador de receptor de androgeno
YU57201A (sh) 16-hidroksiestratrieni kao selektivno aktivni estrogeni
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
PE20020752A1 (es) Esteroides con doble enlace delta 14 sustituido en las posiciones 13 y 14 con actividad androgenica y progestagena
DE50007708D1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
AR029405A1 (es) Oxazolidinonas derivadas de sultamas y sultonas, composiciones farmaceuticas que las comprenden y el uso de las mismas para la manufactura de un medicamento
ECSP993074A (es) Nuevos derivados sustituidos del pirazol

Legal Events

Date Code Title Description
FC Refusal